Suppr超能文献

相似文献

1
Development of potent and selective degraders of PI5P4Kγ.
Eur J Med Chem. 2023 Feb 5;247:115027. doi: 10.1016/j.ejmech.2022.115027. Epub 2022 Dec 24.
3
Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode.
J Med Chem. 2022 Feb 24;65(4):3359-3370. doi: 10.1021/acs.jmedchem.1c01819. Epub 2022 Feb 11.
4
The Identification of Potent, Selective, and Brain Penetrant PI5P4Kγ Inhibitors as In Vivo-Ready Tool Molecules.
J Med Chem. 2023 Jan 12;66(1):804-821. doi: 10.1021/acs.jmedchem.2c01693. Epub 2022 Dec 14.
6
Phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ), a lipid signalling enigma.
Adv Biol Regul. 2016 May;61:47-50. doi: 10.1016/j.jbior.2015.11.007. Epub 2015 Dec 2.
7
Targeting the Dark Lipid Kinase PIP4K2C with a Potent and Selective Binder and Degrader.
Angew Chem Int Ed Engl. 2023 Apr 24;62(18):e202302364. doi: 10.1002/anie.202302364. Epub 2023 Mar 27.
8
Deletion of the gene Pip4k2c, a novel phosphatidylinositol kinase, results in hyperactivation of the immune system.
Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7596-601. doi: 10.1073/pnas.1600934113. Epub 2016 Jun 16.
9
Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor.
Bioorg Med Chem Lett. 2023 Jan 1;79:129083. doi: 10.1016/j.bmcl.2022.129083. Epub 2022 Nov 19.
10
Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitor.
RSC Med Chem. 2023 Apr 17;14(5):934-946. doi: 10.1039/d3md00039g. eCollection 2023 May 25.

引用本文的文献

1
2
Emerging Approaches for Studying Lipid Dynamics, Metabolism, and Interactions in Cells.
Annu Rev Biochem. 2025 Jun;94(1):417-446. doi: 10.1146/annurev-biochem-083024-110827. Epub 2025 Mar 18.
3
PI5P4K inhibitors: promising opportunities and challenges.
FEBS J. 2025 Jan 19. doi: 10.1111/febs.17393.
4
Targeting phosphoinositide signaling in cancer: relevant techniques to study lipids and novel avenues for therapeutic intervention.
Front Cell Dev Biol. 2023 Oct 25;11:1297355. doi: 10.3389/fcell.2023.1297355. eCollection 2023.
7
PROTACs: A novel strategy for cancer drug discovery and development.
MedComm (2020). 2023 May 29;4(3):e290. doi: 10.1002/mco2.290. eCollection 2023 Jun.

本文引用的文献

1
PROTACs: past, present and future.
Chem Soc Rev. 2022 Jun 20;51(12):5214-5236. doi: 10.1039/d2cs00193d.
2
Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode.
J Med Chem. 2022 Feb 24;65(4):3359-3370. doi: 10.1021/acs.jmedchem.1c01819. Epub 2022 Feb 11.
3
Expanding role of PI5P4Ks in cancer: A promising druggable target.
FEBS Lett. 2022 Jan;596(1):3-16. doi: 10.1002/1873-3468.14237. Epub 2021 Dec 7.
4
Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic.
Chembiochem. 2022 Jan 19;23(2):e202100270. doi: 10.1002/cbic.202100270. Epub 2021 Sep 23.
7
Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors.
ACS Med Chem Lett. 2019 Nov 3;11(3):346-352. doi: 10.1021/acsmedchemlett.9b00402. eCollection 2020 Mar 12.
8
Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors.
Cell Chem Biol. 2020 May 21;27(5):525-537.e6. doi: 10.1016/j.chembiol.2020.02.003. Epub 2020 Mar 3.
10
PIP4Ks Suppress Insulin Signaling through a Catalytic-Independent Mechanism.
Cell Rep. 2019 May 14;27(7):1991-2001.e5. doi: 10.1016/j.celrep.2019.04.070.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验